REPL Nov 2024 17.500 call
| Previous Close | 1.1000 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 17.50 |
| Expire Date | 2024-11-15 |
| Day's Range | 1.1000 - 1.1000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 2 |
- GlobeNewswire
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
RP1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent and complete response rate of nearly 22 percent in evaluable patientsSAN DIEGO, April 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the presentation of interim results from ARTACUS, a Phase 1/2 clinical trial evaluating RP1 monotherapy for the tr
- GlobeNewswire
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced the grant of inducement equity awards to Carolyn Trott, the Company’s newly appointed Senior Vice President, Quality Assurance. The inducement awards consist of a non-qualified stock option to purchase 75,000 shares of the Company's common stock and restricted stock units representi
- GlobeNewswire
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization Preparations on track to submit RP1 biologics license application (BLA) in 2H 2024 WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced changes to its executive leadership team designe
